GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (TSE:2160) » Definitions » Total Liabilities

GNI Group (TSE:2160) Total Liabilities : 円29,429 Mil (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is GNI Group Total Liabilities?

GNI Group's Total Liabilities for the quarter that ended in Jun. 2024 was 円29,429 Mil.

GNI Group's quarterly Total Liabilities increased from Dec. 2023 (円26,341.59 Mil) to Mar. 2024 (円27,845.91 Mil) and increased from Mar. 2024 (円27,845.91 Mil) to Jun. 2024 (円29,429.27 Mil).

GNI Group's annual Total Liabilities increased from Dec. 2021 (円11,030.00 Mil) to Dec. 2022 (円14,096.01 Mil) and increased from Dec. 2022 (円14,096.01 Mil) to Dec. 2023 (円26,341.59 Mil).


GNI Group Total Liabilities Historical Data

The historical data trend for GNI Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group Total Liabilities Chart

GNI Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,511.56 10,450.15 11,030.00 14,096.01 26,341.59

GNI Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21,881.40 26,341.59 27,845.91 29,429.27 -

GNI Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GNI Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8193.776+(1750.276+16397.54
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=26,342

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=62394.37-36052.778
=26,342

GNI Group's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10916.821+(1657.35+16855.095
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=29,429

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=68993.563-39564.297
=29,429

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GNI Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of GNI Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group Business Description

Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group Headlines

No Headlines